AVA3996 / Avacta - LARVOL DELTA

AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage to elicit tumor cell kill. (AACR-NCI-EORTC 2023) - No abstract available

Biomarker • Tumor cell • Tumor microenvironment • Oncology • FAP

AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage (AACR 2023) - "The active AVA3996 warhead should therefore be released primarily following FAP cleavage in the tumor microenvironment.Cancer cell lines were assessed for their sensitivity to AVA3996 in vitro: activity was typically 100-fold less than the active warhead or Bortezomib alone. This provides further evidence that AVA3996 can be dosed at higher levels than proteasome inhibitor alone, with the potential for greater tumor targeting and hence reduced systemic toxicity.Ongoing in vivo and co-culture studies aim to further validate the efficacy and tolerability profile of AVA3996 to direct future development of this drug. In addition, the data supports wider utility of the pre|CISION™ platform to target therapeutics to the tumor while reducing systemic dose-limiting toxicities."

Biomarker • Tumor microenvironment • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • FAP • NFKBIA • NF-κβ

Avacta : Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting (Market Screener) - "Avacta Group plc...announces that it has presented pre-clinical data describing the novel pre|CISIONTM proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, USA, one of the largest international cancer research meetings....In a head to head study, AVA2727D kills cancers cells (ex-vivo) as effectively as bortezomib (Takeda's Velcade) which is one of the approved proteasome inhibitors on the market. In three different in-vivo (mouse) cancer models (melanoma, sarcoma and colorectal cancer), AVA3996 was as effective as bortezomib in restricting tumour growth, and in the case of the melanoma model, as effective as trametinib, the standard of care for unresectable melanoma."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Sarcoma • Skin Cancer • Solid Tumor

Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting (Businesswire) - "Avacta Group plc...announces it will present a poster...at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place at Orange County Convention Center, Orlando, Florida on 16 April. The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor."

Preclinical • Oncology • Solid Tumor

"Either AVA6k data or AVA3996 IND but the latter is a little while away yet." (@bluedaysomeday)

"Nothing's a coincidence. Imo takeda are currently in the box seat for AVA3996 licence" (@250kchip)